revenu million
valu usd unless otherwis note
truvada loe cdc donat mean
view earlier week disclos anticip truvada
gener light previou confidenti settlement teva
-- believ slightli earlier prior street assumpt recal
truvada use broadli hiv prophylaxi prep view
increment neg though believ descovi expedit approv
timelin could still enabl cushion convert meaning portion
prep market brand therapi longer exclus
period separ follow convers co believ
recently-announc prep donat cdc uninsur individu
allow prep becom entrench long-term enabl
greater access risk expect materi commerci
impact overal receiv mani question regard
time gener truvada entri believ major investor
concern updat model accordingli pt chang
continu see under-valued
truvada gener expect vs prior expect
disclos week expect truvada gener
septemb part settlement teva
due confidenti natur on-going anda litig truvada
patent expir like prevent clariti previous truvada
sale prep meaning estimate year still
believ could convert prep market descovi given
clear side effect advantag possibl hint efficaci advantag
demonstr discov studi though alway
conserv proport payer would reimburs brand
descovi healthi individu seek prep truvada gener
descovi expedit snda approv timelin use prioriti
review voucher help convert market approv
though lesser time window expect prep
individu switch vs prior estim individu
fewer switch neg impact dcf-deriv price target
increment -- though still show import long-term life
cycl manag need diversif innov
futur
addit announc donat bottles/year
descovy/truvada prep cdc uninsur at-risk individu
compani state align broader initi expand
access hiv drug global well share goal
govern reduc new hiv infect next decad
addit believ make drug avail cdc like help
continu pg
dissemin may produc may price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
base case assum reason sustain hiv
modest price increas convert mani patient
biktarvi meaning price declin hcv
price share stabil worsen volum
beyond gradual strong out-year yescarta uptak
po follow-on indic po
filgotinib ra ibd price target deriv
dcf analysi discount rate termin
growth rate post-taf gener
better expect hcv share retent long-term hiv
price power despit gener entrant success filgotinib
nash product higher revenu car-t product
would lead upsid estim scenario
potenti dcf base valuat would
competit impact hiv hcv franchis greater
expect price pressur slower yescarta uptak failur
expand label failur filgotinib would lead downsid
estim scenario potenti dcf valuat
would
believ biktarvi strong profil robust launch
along favor demograph price dynam
underpin good hiv franchis sustain
nearer-term competit threat overblown expect
maintain strong foundat valuat though
expect continu hcv declin increas competit
recent disrupt entrant share price stabil
provid predict sustain patient
volum still contribut meaning
cash flow next decad expans cellular
therapi solid initi uptak yescarta help establish
core infrastructur addit invest new
modal help provid durabl out-year revenu
growth maintain lead edg new therapeut area
could built upon futur also see filgotinib
potenti blockbust pipelin overal expect
success pipelin diversif cellular therapi
inflamm help drive share appreci
power demograph hiv predict hcv
share price sustain volum
pipelin program filgotinib aggress expans
cellular therapi franchis provid new foundat futur
risk patent expiri competit may impact
lt hiv revenu hcv competitor could compress
pricing/shar near term unknown remain nash
competit unanticip shift eu
potenti catalyst submiss eu ra
potenti fda approv descovi prep
data atla combo nash trial
continu cover
cdc donat contd potenti truvada infring upon cdc patent ultim
uninsur individuals/year could treat though given individu would
overlap commerci insur individu cover government
program medicare/medicaid expect signific revenu impact
believ on-going polici chang relat hiv landscap includ
involv protect class dtc advertis price gener remain worth
watch on-going tdf product liabil case
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand biotechnolog
price target deriv via dcf analysi discount rate termin
growth rate post-taf gener price target support outperform rate
risk rate price target
risk includ gener hiv entrant competit hcv price pressur commerci
scientif complex cellular car-t therapi efficaci safeti risk pipelin
product filgotinib
gilead leader develop market anti-infect drug approv
product treatment hiv/aid hepat hepat pulmonolog diseas
gilead develop pipelin antivir liver diseas inflamm cellular therapi
oncolog gilead extens world-wide sale market infrastructur
